Page 229 - Read Online

J, Seto T, Satouchi M, Tada H, Hirashima T, Asami K, Katakami N, Alloisio M, Santoro A, Varella-Garcia M. Increased MET gene copy
Takada M, Yoshioka H, Shibata K, Kudoh S, Shimizu E, Saito H, number negatively affects survival of surgically resected non-small-
Toyooka S, Nakagawa K, Fukuoka M; West Japan Oncology Group. cell lung cancer patients. J Clin Oncol 2009;27:1667-74.
Gefitinib versus cisplatin plus docetaxel in patients with non-small- 15. Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald
cell lung cancer harbouring mutations of the epidermal growth factor NT, Massion PP, Siwak-Tapp C, Gonzalez A, Fang R, Mark EJ,
receptor (WJTOG3405): an open label, randomised phase 3 trial. Batten JM, Chen H, Wilner KD, Kwak EL, Clark JW, Carbone DP,
Lancet Oncol 2010;11:121-8. Ji H, Engelman JA, Mino-Kenudson M, Pao W, Iafrate AJ. ROS1
6. Zhou C, Wu Y-L, Chen G, Feng J, Liu X-Q, Wang C, Zhang S, rearrangements define a unique molecular class of lung cancers. J
Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C, Luo Y, Chen Clin Oncol 2012;30:863-70.
L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, Zhang L, You C. 16. Zinner RG, Glisson BS, Fossella FV, Pisters KM, Kies MS, Lee PM,
Erlotinib versus chemotherapy as first-line treatment for patients Massarelli E, Sabloff B, Fritsche HA Jr, Ro JY, Ordonez NG, Tran HT,
with advanced EGFR mutation-positive non-smallcell lung cancer Yang Y, Smith TL, Mass RD, Herbst RS. Trastuzumab in combination
(OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, with cisplatin and gemcitabine in patients with Her2-overexpressing,
phase 3 study. Lancet Oncol 2011;12:735-42. untreated, advanced non-small cell lung cancer: report of a phase II
7. Sahoo R, Harini VV, Babu VC, Patil Okaly GV, Rao S, Nargund A, trial and findings regarding optimal identification of patients with
Venkataswamy E, Rao R, Kumar BS. Screening for EGFR mutations Her2-overexpressing disease. Lung Cancer 2004;44:99-110.
in lung cancer, a report from India. Lung Cancer 2011;73:316-9. 17. Kinno T, Tsuta K, Shiraishi K, Mizukami T, Suzuki M, Yoshida
8. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, A, Suzuki K, Asamura H, Furuta K, Kohno T, Kushima R.
Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, Bando M, Ohno Clinicopathological features of nonsmall cell lung carcinomas with
S, Ishikawa Y, Aburatani H, Niki T, Sohara Y, Sugiyama Y, Mano H. BRAF mutations. Ann Oncol 2014;25:138-42.
Identification of the transforming EML4- ALK fusion gene in non- 18. Ichimura E, Maeshima A, Nakajima T, Nakamura T. Expression of
small-cell lung cancer. Nature 2007;448:561-6. c-met/HGF receptor in human non-small cell lung carcinomas in
9. Camidge DR, Bang Y-J, Kwak EL, Iafrate AJ, Varella-Garcia M, vitro and in vivo and its prognostic significance. Jpn J Cancer Res
Fox SB, Riely GJ, Solomon B, Ou SH, Kim DW, Salgia R, Fidias P, 1996;87:1063-9.
Engelman JA, Gandhi L, Jänne PA, Costa DB, Shapiro GI, Lorusso 19. Kohno T, Ichikawa H, Totoki Y, Yasuda K, Hiramoto M, Nammo T,
P, Ruffner K, Stephenson P, Tang Y, Wilner K, Clark JW, Shaw AT. Sakamoto H, Tsuta K, Furuta K, Shimada Y, Iwakawa R, Ogiwara
Activity and safety of crizotinib in patients with ALK-positive non- H, Oike T, Enari M, Schetter AJ, Okayama H, Haugen A, Skaug V,
small-cell lung cancer: updated results from a phase 1 study. Lancet Chiku S, Yamanaka I, Arai Y, Watanabe S, Sekine I, Ogawa S, Harris
Oncol 2012;13:1011-9. CC, Tsuda H, Yoshida T, Yokota J, Shibata T. KIF5B-RET fusions in
10. Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone lung adenocarcinoma. Nat Med 2012;18:375-7.
G, Jenkins RB, Kwiatkowski DJ, Saldivar JS, Squire J, Thunnissen E,
Ladanyi M. Molecular testing guideline for selection of lung cancer 20. Rekhtman N, Paik PK, Arcila ME, Tafe LJ, Oxnard GR, Moreira
patients for EGFR and ALK tyrosine kinase inhibitors: guideline AL, Travis WD, Zakowski MF, Kris MG, Ladanyi M. Clarifying
from the College of American Pathologists, international association the spectrum of driver oncogene mutations in biomarker-verified
for the study of lung cancer, and Association for Molecular Pathology. squamous carcinoma of lung: lack of EGFR/KRAS and presence of
Arch Pathol Lab Med 2013;137:828-60. PIK3CA/AKT1 mutations. Clin Cancer Res 2012;18:1167-76.
11. Leighl NB, Rekhtman N, Biermann WA, Huang J, Mino-Kenudson 21. Heist RS, Mino-Kenudson M, Sequist LV, Tammireddy S, Morrissey
M, Ramalingam SS, West H, Whitlock S, Somerfield MR. Molecular L, Christiani DC, Engelman JA, Iafrate AJ. FGFR1 amplification in
Testing for selection of patients with lung cancer for epidermal growth squamous cell carcinoma of the lung. J Thorac Oncol 2012;7:1775-80.
factor receptor and anaplastic lymphoma kinase tyrosine kinase 22. Heist RS, Sequist LV, Engelman JA. Genetic changes in squamous
inhibitors: American Society of Clinical Oncology Endorsement cell lung cancer: a review. J Thorac Oncol 2012;7:924-33.
of the College of American Pathologists/International Society for 23. Marks JL, Gong Y, Chitale D, Golas B, McLellan MD, Kasai Y, Ding
the study of lung cancer/Association of Molecular Pathologists L, Mardis ER, Wilson RK, Solit D, Levine R, Michel K, Thomas RK,
Guideline. J Clin Oncol 2014;32:3673-9. Rusch VW, Ladanyi M, Pao W. Novel MEK1 mutation identified by
12. Balak MN, Gong Y, Riely GJ, Somwar R, Li AR, Zakowski MF, mutational analysis of epidermal growth factor receptor signaling
Chiang A, Yang G, Ouerfelli O, Kris MG, Ladanyi M, Miller VA, pathway genes in lung adenocarcinoma. Cancer Res 2008;68:5524-8.
Pao W. Novel D761Y and common secondary T790M mutations 24. Rizvi NA, Shepherd FA, Antonia SJ, Brahmer JR, Chow LQ,
in epidermal growth factor receptor-mutant lung adenocarcinomas Goldman J, Juergens R, Borghaei H, Ready NE, Gerber DE, Shen
with acquired resistance to kinase inhibitors. Clin Cancer Res Y, Harbison C, Chen AC, Gettinger S. First-Line Monotherapy With
2006;12:6494-501. Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Advanced
13. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park Non-Small Cell Lung Cancer (NSCLC): Safety, Efficacy, and
JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes Correlation of Outcomes With PD-L1 Status. Poster 165, Chicago
AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley Multidisciplinary Symposium in Thoracic Oncology (CMSTO)
LC, Jänne PA. MET amplification leads to gefitinib resistance in lung Annual Meeting, 2014;90:S31.
cancer by activating ERBB3 signaling. Science 2007;316:1039-43. 25. Sienel W, Varwerk C, Linder A, Kaiser D, Teschner M, Delire M,
14. Cappuzzo F, Marchetti A, Skokan M, Rossi E, Gajapathy S, Felicioni Stamatis G, Passlick B. Melanoma associated antigen (MAGE)-A3
L, Del Grammastro M, Sciarrotta MG, Buttitta F, Incarbone M, expression in Stages I and II non-small cell lung cancer: results of a
Toschi L, Finocchiaro G, Destro A, Terracciano L, Roncalli M, multi-center study. Eur J Cardiothorac Surg 2004;25:131-4.

Journal of Cancer Metastasis and Treatment ¦ Volume 2 ¦ June 15, 2016 ¦ 219